Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (MOVE) pioneers wearable health technology that transforms personal wellness through medical-grade data collection. This page aggregates official announcements, financial updates, and strategic developments from the creator of the Evie Ring—a women-focused wearable tracking metabolic health indicators like glucose trends and heart rate variability.
Investors and industry observers will find curated press releases covering product launches, FDA clearances, and enterprise partnerships. Key updates include earnings reports, clinical validation milestones, and expansions into chronic disease management markets. All content is vetted for accuracy and relevance to health tech innovation.
Bookmark this page for streamlined access to Movano's evolving role in bridging consumer wearables with clinical insights. Check regularly for developments in sensor technology advancements and new applications of its AI-driven health analytics platform.
Movano Health (MOVE) announced positive results from an 81-participant blood pressure clinical study for its proprietary cuffless blood pressure device. The wrist-worn prototype achieved a mean absolute difference (MAD) of 4.9 mmHg, surpassing the FDA requirement of 7 mmHg MAD for wearable devices.
The latest prototype features 12 additional mmWave antennas integrated with the company's custom IC, enabling enhanced data collection and a slimmer design. The device can also monitor vital signs including pulse rate, SpO2, respiration rate, and ECG waveforms. The IRB-approved study, conducted at Movano Health Clinical Lab, compared the prototype against a hospital-grade FDA-cleared blood pressure monitor.
With hypertension affecting over 122 million Americans and 59 million having prehypertension, Movano Health is preparing for a pivotal trial to meet FDA clinical requirements, with a consumer-oriented device expected in the coming months.
Movano Health (Nasdaq: MOVE) has announced significant updates to its Evie Ring companion app, enhancing support for women's wellness tracking. The new features, available on iOS, include Apple Health integration and expanded data visualization capabilities.
Key improvements include new 7- and 30-day trend graphs for sleep metrics from medical-grade sensors, daily basal body temperature logging, and heart rate mapping with activity state tracking. The app now offers enhanced workout tracking with manual post-workout logging and displays menstrual cycle information on the Daily Summary screen.
The Evie Ring, priced at $269 with no subscription fees, is HSA/FSA eligible and compatible with both Apple and Android devices. It's available in gold, rose gold, and silver finishes, in sizes 5-12, with an optional complimentary sizing kit.
Movano Health (MOVE) has initiated a blood pressure clinical trial featuring its new cuffless blood pressure wrist wearable. The study, scheduled for completion in the second week of February 2025, will involve at least 70 participants and compare pulse pressure waveforms against a hospital-grade device.
The enhanced wearable will monitor multiple vital signs, including pulse rate, blood oxygen saturation (SpO2), respiration rate, and ECG waveforms. This trial follows three previous studies conducted between October 2023 and November 2024, which collected data from over 60 participants of diverse demographics.
The company plans to conduct an additional 100-150 person continuous-blood pressure study using an arterial line in mid-2025, aimed at finalizing the algorithm for a future FDA pivotal trial.
Movano Health (MOVE) has announced the beta release of EvieAI, a virtual wellness assistant integrated into their Evie smart ring's companion app. This feature marks the first medical journal-trained AI companion in a wearable device, trained on over 100,000 medical journals.
The AI assistant will provide personalized health insights based on users' metrics collected by Evie's sensors, including heart rate, blood oxygen, menstrual cycle information, skin temperature, sleep, exercise, and mood. Unlike general AI assistants, EvieAI focuses on medical accuracy and implements industry-standard encryption for data protection.
The Evie Ring, priced at $269 with no subscription fees, features 4+ days of battery life, 60-minute recharge time, and is available in gold, rose gold, and silver finishes. The beta version of EvieAI is currently available for iOS users at no additional cost to existing customers.
Movano Health (Nasdaq: MOVE) has appointed Dr. Shaheen Wirk to its Board of Directors. Dr. Wirk brings over 20 years of investment experience in life science companies and is the founder and Chief Investment Officer of Palkon Capital Management. This appointment follows Movano's recent FDA 510(k) clearance for the pulse oximeter in its EvieMED Ring.
The FDA clearance positions Movano to pursue multi-billion dollar opportunities in health monitoring solutions, particularly in clinical trials, post-clinical trial management, and remote patient monitoring. The company's first product, the Evie Ring wellness device, is currently available in the market through eviering.com.
Dr. Wirk's extensive background includes founding Blue Cotinga advisory firm and serving on boards including Tvardi Therapeutics. He holds M.D., M.B.A., and B.S. degrees from Duke University and completed research training in oncology and trauma surgery at prestigious institutions.
Movano Health has received FDA 510(k) clearance for the pulse oximeter in its EvieMED Ring, opening up a $40 billion healthcare B2B market opportunity. The clearance enables the company to pursue opportunities in clinical trials, post-clinical management, and remote patient monitoring. The company is already in agreement phase with a large payor for a pilot study planned for early 2025 and in discussions with pharmaceutical companies and CROs. The EvieMED Ring combines medical-grade accuracy with comfortable wearability, measuring blood oxygen levels, heart rate, and additional wellness metrics. A pivotal study confirmed accurate readings across all skin tones.
Movano Health (MOVE) reported Q3 2024 results, highlighting three key initiatives: the successful back-in-stock launch of Evie Ring direct-to-consumer business, pursuing FDA 510(k) clearance for EvieMED Ring, and advancing blood pressure and glucose monitoring studies. The company shipped 339 Evie Rings in Q3, reporting an operating loss of $7.4 million compared to $9.1 million in Q3 2023. Cash position stood at $11.3 million as of September 30, 2024. The company implemented a 1-for-15 reverse stock split and regained Nasdaq compliance. They also entered agreement phase with a healthcare company for an EvieMED Ring pilot program in Q1 2025.
Movano Health (Nasdaq: MOVE) has completed testing of its new blood pressure wrist wearable during a hypoxia clinical trial at UC San Francisco. The enhanced device features 12 additional mmWave antennas and a custom IC, delivering improved data collection with a slimmer, more comfortable design. The wearable also monitors vital signs including pulse rate, blood oxygen saturation, respiration rate, and ECG waveforms.
This study follows two clinical trials from October 2023 and June 2024, where the company's non-invasive device collected pulse pressure waveforms data from over 50 participants. The device improvements were implemented based on learnings from these previous studies to achieve higher fidelity blood pressure signals.
Movano Health (Nasdaq: MOVE) has scheduled its third quarter 2024 financial results release for Thursday, November 14, 2024, after market close. The company will host a conference call and live audio webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the webcast through the company's investor relations website or join via phone using provided domestic and international dial-in numbers. A recorded version will be available on the company's website for two years.
Movano Health (NASDAQ: MOVE) has submitted a complete response package to the FDA for the final review phase of its 510(k) application for the EvieMED Ring. The company remains optimistic about receiving 510(k) clearance for this wearable device. The EvieMED Ring combines medical functionality through pulse oximetry with wellness tracking features, including sleep monitoring, activity tracking, and mood and energy logging capabilities. The company sees potential opportunities in remote patient monitoring and clinical trials markets.
FAQ
What is the current stock price of Movano (MOVE)?
What is the market cap of Movano (MOVE)?
